Pharmaceutical giant AstraZeneca's (NYSE:AZN) has had a tough go lately. Its stock has left investors disappointed, rising less than 3% over the past five years. The company's facing tough times, with patent expirations that have slammed the industry as a whole taking an especially huge toll on AstraZeneca's sales. The company's pipeline offers a fair amount of lackluster products, but AstraZeneca's looking toward acquisitions as it tries to invigorate a murky future.
Is this the right path for this troubled big pharma? AstraZeneca dabbled in buyouts earlier this year and has been mentioned as a suitor for biotech standout Onyx Pharmaceuticals (UNKNOWN:ONXX.DL), but the company has yet to show investors any real payoff.
In the video below, Fool contributor Dan Carroll takes you through the latest with AstraZeneca's acquisition ambitions -- and whether this strategy can save its clouded future.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.